Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA502001
Max Phase: Preclinical
Molecular Formula: C15H27NO11
Molecular Weight: 397.38
Molecule Type: Small molecule
Associated Items:
ID: ALA502001
Max Phase: Preclinical
Molecular Formula: C15H27NO11
Molecular Weight: 397.38
Molecule Type: Small molecule
Associated Items:
Synonyms (1): Methyl N-Acetyllactosaminide
Synonyms from Alternative Forms(1):
Canonical SMILES: CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1NC(C)=O
Standard InChI: InChI=1S/C15H27NO11/c1-5(19)16-8-10(21)13(7(4-18)26-14(8)24-2)27-15-12(23)11(22)9(20)6(3-17)25-15/h6-15,17-18,20-23H,3-4H2,1-2H3,(H,16,19)/t6-,7-,8-,9+,10-,11+,12-,13-,14-,15+/m1/s1
Standard InChI Key: PKPZITUQXLANSE-AEBMIEDASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 397.38 | Molecular Weight (Monoisotopic): 397.1584 | AlogP: -4.60 | #Rotatable Bonds: 6 |
Polar Surface Area: 187.40 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.91 | CX Basic pKa: | CX LogP: -4.35 | CX LogD: -4.35 |
Aromatic Rings: 0 | Heavy Atoms: 27 | QED Weighted: 0.23 | Np Likeness Score: 1.70 |
1. Giguère D, Bonin MA, Cloutier P, Patnam R, St-Pierre C, Sato S, Roy R.. (2008) Synthesis of stable and selective inhibitors of human galectins-1 and -3., 16 (16): [PMID:18674915] [10.1016/j.bmc.2008.06.044] |
2. Salameh BA, Cumpstey I, Sundin A, Leffler H, Nilsson UJ.. (2010) 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors., 18 (14): [PMID:20538469] [10.1016/j.bmc.2010.05.040] |
3. van Hattum H, Branderhorst HM, Moret EE, Nilsson UJ, Leffler H, Pieters RJ.. (2013) Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1., 56 (3): [PMID:23281927] [10.1021/jm301677r] |
Source(1):